VS-7375 Demonstrates Robust Anti-Tumor Activity Across Advanced KRAS G12D-Mutant Cancers, Highlighted by 50% Confirmed ORR in 2L Pancreatic Ductal Adenocarcinoma and Two Complete Responses in 2L+ Dise

Go back to VS-7375 Demonstrates Robust Anti-Tumor Activity Across Advanced KRAS G12D-Mutant Cancers, Highlighted by 50% Confirmed ORR in 2L Pancreatic Ductal Adenocarcinoma and Two Complete Responses in 2L+ Dise
VERASTEM SHS (NASDAQ: VSTM) Delayed: 10.06 +0.85 (9.23%)
Previous Close $9.21    52 Week High $2.43 
Open $9.20    52 Week Low $1.05 
Day High $10.11    P/E N/A 
Day Low $9.14    EPS $-1.79 
Volume 5,947,213